Glucagon-like peptide 1-baseret behandling af type 2-diabetes mellitus

Research output: Contribution to journal › Review › Research › peer-review

Standard

Glucagon-like peptide 1-baseret behandling af type 2-diabetes mellitus. / Knop, Filip Krag; Vilsbøll, Tina.

In: Ugeskrift for Laeger, Vol. 169, No. 22, 28.05.2007, p. 2095-9.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Knop, FK & Vilsbøll, T 2007, 'Glucagon-like peptide 1-baseret behandling af type 2-diabetes mellitus', Ugeskrift for Laeger, vol. 169, no. 22, pp. 2095-9.

APA

Knop, F. K., & Vilsbøll, T. (2007). Glucagon-like peptide 1-baseret behandling af type 2-diabetes mellitus. Ugeskrift for Laeger, 169(22), 2095-9.

Vancouver

Knop FK, Vilsbøll T. Glucagon-like peptide 1-baseret behandling af type 2-diabetes mellitus. Ugeskrift for Laeger. 2007 May 28;169(22):2095-9.

Author

Knop, Filip Krag ; Vilsbøll, Tina. / Glucagon-like peptide 1-baseret behandling af type 2-diabetes mellitus. In: Ugeskrift for Laeger. 2007 ; Vol. 169, No. 22. pp. 2095-9.

Bibtex

@article{bf0bffd19e22462faaa1b173bd57cb4c,
title = "Glucagon-like peptide 1-baseret behandling af type 2-diabetes mellitus",
abstract = "GLP-1 is secreted from the small intestine in response to ingestion of nutrients. It has a powerful insulinotropic effect and stimulates beta-cell growth and is therefore being developed for treatment of type 2 diabetes. The GLP-1 analogue, exenatide, is on the market in the USA as an add-on therapy. Another strategy to increase circulating GLP-1 is to inhibit the enzyme DPP-IV which degrades endogenous GLP-1. GLP-1-based therapy results in HbA1c reductions of approximately 1 percent point, and the lack of serious side effects and the low risk of hypoglycaemic episodes are unique traits.",
author = "Knop, {Filip Krag} and Tina Vilsb{\o}ll",
year = "2007",
month = may,
day = "28",
language = "Dansk",
volume = "169",
pages = "2095--9",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "22",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide 1-baseret behandling af type 2-diabetes mellitus

AU - Knop, Filip Krag

AU - Vilsbøll, Tina

PY - 2007/5/28

Y1 - 2007/5/28

N2 - GLP-1 is secreted from the small intestine in response to ingestion of nutrients. It has a powerful insulinotropic effect and stimulates beta-cell growth and is therefore being developed for treatment of type 2 diabetes. The GLP-1 analogue, exenatide, is on the market in the USA as an add-on therapy. Another strategy to increase circulating GLP-1 is to inhibit the enzyme DPP-IV which degrades endogenous GLP-1. GLP-1-based therapy results in HbA1c reductions of approximately 1 percent point, and the lack of serious side effects and the low risk of hypoglycaemic episodes are unique traits.

AB - GLP-1 is secreted from the small intestine in response to ingestion of nutrients. It has a powerful insulinotropic effect and stimulates beta-cell growth and is therefore being developed for treatment of type 2 diabetes. The GLP-1 analogue, exenatide, is on the market in the USA as an add-on therapy. Another strategy to increase circulating GLP-1 is to inhibit the enzyme DPP-IV which degrades endogenous GLP-1. GLP-1-based therapy results in HbA1c reductions of approximately 1 percent point, and the lack of serious side effects and the low risk of hypoglycaemic episodes are unique traits.

M3 - Review

VL - 169

SP - 2095

EP - 2099

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 22

ER -

ID: 34145124